Top 5 Pharmacy Times Clostridioides difficile Articles of 2023
From newsworthy moments to groundbreaking research, these were the most-read Clostridioides difficile-related articles on Pharmacy Times in 2023.
1. Community-associated C. Difficile Infection Is Rising; Disease Carries Significant Social, Economic Burden
Clostridioides difficile infection can have a significant impact on feelings of depression and anxiety, while worsening quality of life. Read More Here.
Dr_Microbe - stock.adobe.com
2. Clinical Overview: Steps to Implementation of Rebyota for Recurrent C. difficile Infection
Rebyota is a live biotherapeutic product that is unfamiliar to many pharmacists and other health care providers, and it has unique steps in the administration process. Read More Here.
3. Open-Label Clinical Trials Have Higher Cure Rate of Recurrent C. Diff Infection Compared to Randomized Clinical Trials
Randomized clinical trials still showed that microbiota restoration is significantly more effective than antibiotics for recurrent Clostridioides difficile infection. Read More Here.
4. Phase 2 Trial Data Show That Novel Antibiotic Led to 96% Cure Rate for C diff Infection
Iberzaplstat was non-inferior to standard of care vancomycin, was safe and tolerable, and will advance into a phase 3 trial. Read More Here.
5. Common Antibiotics Associated with C. difficile Infection Include Piperacillin, Meropenem
Antibiotics that were found to be most commonly associated with Clostridioides difficile infection are piperacillin/tazobactam, meropenem, vancomycin, ciprofloxacin, ceftriaxone, and levofloxacin, according to a recent study. Read More Here.
